Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage
- 49 Downloads
The initial dose-escalating clinical trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage is reported. AT877 is characterized by its strong spasmolytic activity, its inhibition of intracellular calcium ion activity, and the inhibiton of several protein kinases.
A total of 113 patients (Hunt and Hess grades I to IV) who had undergone surgery within 3 days of aneurysmal rupture entered the study. Patients were divided into 5 groups according to the total daily dose of AT877: I: 20 mg; II: 40 mg; III: 60 mg; IV: 90 mg; and V: 120–180 mg. AT877 was given by intravenous infusion over 30 min two or three times a day for 14 days after surgery.
Although AT877 did not completely abolish angiographic vasospasm, severe vasospasm was seen less frequently in patients given higher doses. Vasospasm was the cause of a poor clinical outcome (Glasgow outcome scale rating 3 or greater) in 19%, 7%, 9%, 8%, and 6% of the patients in groups I to V, respectively. The results indicated a favourable clinical effect of AT877 at doses above 40 mg per day. Only mild hypotension was seen, even when 60 mg of AT877 was infused over 30 min.
AT877 appears to be effective in patients with subarachnoid haemorrhage. Part of its effect may be attributable to protection of the brain from ischaemic insults due to chronic cerebral vasospasm. However, the drug still needs to be evaluated in a placebo-controlled double-blind trial (which is currently being carried out).
KeywordsSubarachnoid haemorrhage chronic cerebral vasospasm calcium antagonist AT877 HA 1077
Unable to display preview. Download preview PDF.
- 1.Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SG, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits De, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR (1983) Cerebral arterial spasm —A controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619–624PubMedGoogle Scholar
- 13.Petruk KC, West M, Mohr G, Weir BKA, Benoit BG, Gentili F, Disney LB, Khan MI, Grace M, Holness RO, Karwon MS, Ford RM, Cameron GS, Tucker WS, Purves GV, Miller JDR, Hunter KM, Richard MT, Durity FA, Chan R, Clein LJ, Maroun FB, Godon A (1988) Nimodipine treatment in poor-grade aneurysm patients. J Neurosurg 68: 505–517PubMedGoogle Scholar
- 14.Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P (1986) Prevention of vasospasm in subarachnoid haemorrhage: A controlled study with nimodipine. Acta Neurochir (Wien) 82: 110–114, 1986Google Scholar
- 15.Pickard JD, Murray GD, Illingworth R, Shaw MDM, Teasdale GM, Foy PM, Humphrey PRD, Lang DA, Nelson R, Richards P, Sinar J, Bailey S, Skene A (1989) Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Br Med J 298: 636–642Google Scholar
- 17.Shibuya M, Suzuki Y, Takayasu M, Asano T, Harada T, Ikegaki I, Satoh S, Hidaka H (1988) The effects of an intracellular calcium antagonist, HA1077, on delayed cerebral vasospasm in dogs. Acta Neurochir (Wien) 90: 53–59Google Scholar